Figure S1.

Long-term donor chimerism is established by M-HSCT, related to Figure 1

(A) Schematic of the M-HSCT strategy, illustrating the proposed exchange between mobilized recipient CD45.2 (in gray) and donor CD45.1 cells (in purple).

(B) Schematic of the interaction between mobilization agents and their therapeutic targets within the BM microenvironment.

(C) Representative plots showing the gating strategy used to characterize LSK and SLAM HSC circulating in the peripheral blood, stained for lineage markers, SCA1, KIT, CD48, and CD150.

(D) Representative plots showing the gating strategy used to characterize the donor cells, extracted from the BM, stained for lineage markers, SCA1, KIT, pre-, and post-purification of lineage negative cells. In all the analyses, p less than 0.05 were considered significant (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. “ns” means non-significance).